Laura Beretta
Department of Molecular and Cellular Oncology, Division of Discovery Science
Present Title & Affiliation
Primary Appointment
Professor, Department of Molecular and Cellular Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX
Education & Training
Degree-Granting Education
| 1989 | University of Paris 6, Paris, FRA, PHD, Molecular and Cellular Pharmacology |
| 1985 | University of Paris 6, Paris, FRA, DEA, Molecular and Cellular Pharmacology |
| 1984 | University of Paris 6, Paris, FRA, MS, Physiology |
| 1983 | University of Paris 6, Paris, FRA, BS, Cellular Biology and Physiology |
Postgraduate Training
| 1992-1995 | Postdoctoral Fellowship, McGill University, Montreal |
Grant & Contract Support
| Date: | 2020 - 2022 |
| Title: | Targeting STAT3 to Prevent Hepatocellular Carcinoma (HCC) Associated with Non-Alcoholic Steatohepatitis (NASH) |
| Funding Source: | NIH/NCI |
| Role: | Co-Principal Investigator |
| Date: | 2020 - 2023 |
| Title: | Adipocyte-Producing Noncoding RNA Promotes Liver Cancer Immunoresistance |
| Funding Source: | Cancer Prevention & Research Institute of Texas (CPRIT) |
| Role: | Co-Investigator |
| ID: | RP200423 |
| Date: | 2019 - 2024 |
| Title: | The University of Texas MD Anderson Cancer Center SPORE in Hepatocellular Carcinoma |
| Funding Source: | NIH/NCI |
| Role: | Contact PI, Admin Core Dir, Co-Leader Project 3 |
| ID: | 1P50CA217674-01A1 |
| Date: | 2018 - 2021 |
| Title: | Modeling the Risk of Significant Liver Fibrosis in Obesity and Diabetes |
| Funding Source: | MD Anderson Cancer Center (MDACC-MRP) |
| Role: | Principal Investigator |
| Date: | 2018 - 2021 |
| Title: | Prevention of Hepatocellular Carcinoma (HCC) associated with Non-Alcoholic Steatohaptitis (NASH) |
| Funding Source: | NIH/NCI |
| Role: | Principal Investigator |
| ID: | HHSN261201500018I-HHSN26100007 |
| Date: | 2018 - 2023 |
| Title: | HCC Genomics in the Hispanic population of Texas |
| Funding Source: | NIH/NCI |
| Role: | Principal Investigator |
| ID: | 1R01CA204665-01A1 |
| Date: | 2018 - 2022 |
| Title: | Clinical trials of C188-9, an oral inhibitor of signal transducer and activator of transcription (STAT) 3, in patients with hepatocellular carcinoma (HCC) |
| Funding Source: | Cancer Prevention & Research Institute of Texas (CPRIT) |
| Role: | Co-Investigator |
| ID: | RP180473 |
| Date: | 2016 - 2022 |
| Title: | Imaging and early detection of Hepatocellular Carcinoma |
| Funding Source: | NIH/NCI |
| Role: | Principal Investigator |
| ID: | CA195524-01A1 |
| Date: | 2015 - 2017 |
| Title: | Biomarkers for the Early Detection of Hepatocellular Carcinoma |
| Funding Source: | McCombs Institute Center MD Anderson Cancer Center |
| Role: | Principal Investigator |
Selected Publications
Peer-Reviewed Articles
- Kwan SY, Jiao J, Joon A, Wei P, Petty LE, Below JE, Daniel CR, Wu X, Zhang J, Jenq RR, Futreal PA, Hawk ET, McCormick JB, Fisher-Hoch SP, Beretta L. Gut Microbiome Features Associated with Liver Fibrosis in Hispanics, a Population at High Risk for Fatty Liver Disease. Hepatology 75(4):955-967, 2022. e-Pub 2021. PMID: 34633706.
- Sanchez JI, Jiao J, Kwan SY, Veillon L, Warmoes MO, Tan L, Odewole M, Rich NE, Wei P, Lorenzi PL, Singal AG, Beretta L. Lipidomic Profiles of Plasma Exosomes Identify Candidate Biomarkers for Early Detection of Hepatocellular Carcinoma in Patients with Cirrhosis. Cancer Prev Res (Phila) 14(10):955-962, 2021. e-Pub 2021. PMID: 34253566.
- Jiao J, Kwan SY, Sabotta CM, Tanaka H, Veillon L, Warmoes MO, Lorenzi PL, Wang Y, Wei P, Hawk ET, Almeda JL, McCormick JB, Fisher-Hoch SP, Beretta L. Circulating Fatty Acids Associated with Advanced Liver Fibrosis and Hepatocellular Carcinoma in South Texas Hispanics. Cancer Epidemiol Biomarkers Prev 30(9):1643-1651, 2021. e-Pub 2021. PMID: 34155064.
- Khan IM, Gjuka D, Jiao J, Song X, Wang Y, Wang J, Wei P, El-Serag HB, Marrero JA, Beretta L. A Novel Biomarker Panel for the Early Detection and Risk Assessment of Hepatocellular Carcinoma in Patients with Cirrhosis. Cancer Prev Res (Phila), 2021. e-Pub 2021. PMID: 33685927.
- Kwan SY, Jiao J, Qi J, Wang Y, Wei P, McCormick JB, Fisher-Hoch SP, Beretta L. Bile Acid Changes Associated With Liver Fibrosis and Steatosis in the Mexican-American Population of South Texas. Hepatol Commun 4(4):555-568, 2020. e-Pub 2020. PMID: 32258950.
- Nguyen J, Jiao J, Smoot K, Watt GP, Zhao C, Song X, Stevenson HL, McCormick JB, Fisher-Hoch SP, Zhang J, Futreal PA, Beretta L. Toll-like receptor 4: a target for chemoprevention of hepatocellular carcinoma in obesity and steatohepatitis. Oncotarget 29(9(50)):29495-29507, 2018. e-Pub 2018. PMID: 30034633.
- Jung KH, Yoo W, Stevenson HL, Deshpande D, Shen H, Gagea M, Yoo SY, Wang J, Eckols TK, Bharadwaj U, Tweardy DJ, Beretta L. Multifunctional Effects of a Small-Molecule STAT3 Inhibitor on NASH and Hepatocellular Carcinoma in Mice. Clin Cancer Res 23(18):5537-5546, 2017. e-Pub 2017. PMID: 28533225.
Patient Reviews
CV information above last modified March 13, 2023